Much more than you expected: The non-DHFR-mediated effects of methotrexate

• Published in: Biochimica et biophysica acta. General subjects Vol. 1861; no. 3; pp. 499 - 503
• Main Authors: Sramek, Martin, Neradil, Jakub, Veselska, Renata
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier B.V 01.03.2017
• Subjects: Animals; autoimmune diseases; Cell differentiation; dihydrofolate reductase; DNA methylation; Epigenetic regulation; folic acid; Folic Acid - metabolism; Folic Acid Antagonists - pharmacology; Folic Acid Antagonists - therapeutic use; Histone acetylation; Humans; Methotrexate; Methotrexate - pharmacology; Methotrexate - therapeutic use; Oxidative stress; pharmacology; Signal Transduction - drug effects; Tetrahydrofolate Dehydrogenase - metabolism; therapeutics; ALL; MAT; Oxidative stress; DHF; HDACs; MTXPGs; Glo1; Epigenetic regulation; RFC; MTX; FGAR; ATIC; THF; TMECG; FPGS; E2F1; DNA methylation; Methotrexate; HDACi; SAHA; MTHFR; MITF; PP2A; Histone acetylation; Cell differentiation; FAICAR; DHFR; HDACis; ROS; GAR; HATs; AICAR; SAH; ATRA; GART; ADA; SAM; TS

For decades, methotrexate (MTX; amethopterin) has been known as an antifolate inhibitor of dihydrofolate reductase (DHFR), and it is widely used for the treatment of various malignancies and autoimmune diseases. Although the inclusion of MTX in various therapeutic regimens is based on its ability to...